Vera Therapeutics Q2 loss widens less than expected
VERA•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the biotechnology & medical research peer group is "buy".
- Wall Street's median 12-month price target for Vera Therapeutics, Inc. is $78.00, about 137.2% above its August 7 closing price of $32.89.
Outlook and result drivers
- The company expects the final efficacy analysis from the ORIGIN 3 trial in Q3 2026.
- It anticipates sBLA submission to the FDA in Q4 2026.
- Potential full approval of TRUTAKNA in IgAN is expected in 2027.
Result drivers
- TRUTAKNA launch - The company cited the accelerated FDA approval and commercial launch of TRUTAKNA for IgA nephropathy as a key milestone.
- Clinical profile - The company highlighted TRUTAKNA's Phase 3 trial results showing reduction in proteinuria and a favorable safety profile.
- Commercial execution - The company pointed to an experienced team and an early encouraging reception for TRUTAKNA in the U.S. market.
